Shares of Glenmark Pharma were higher by up to 2% in early trade on December 16 after the company's US business launched its own version of the anti-epileptic drug Lacosamide, which is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback